Core Insights - Soligenix is entering a pivotal year with significant clinical and regulatory milestones, particularly the interim analysis of the Phase 3 FLASH2 trial for HyBryte™ in Q2 2026 and top-line results expected in H2 2026 [2] Recent Accomplishments - The European Commission granted orphan drug designation to dusquetide (SGX945) for Behçet's Disease on March 26, 2026, following a positive recommendation from the EMA [2] - Findings from supportive trials of HyBryte™ for CTCL were presented at the United States Cutaneous Lymphoma Consortium Workshop on March 23, 2026 [2] - A summary of clinical trials for HyBryte™ was published in the peer-reviewed journal Expert Opinion on Investigational Drugs on March 19, 2026 [2] - SGX945 received Promising Innovative Medicine designation in the UK for Behçet's Disease on March 10, 2026 [2] - The EMA COMP provided a positive recommendation for orphan drug designation for dusquetide on February 26, 2026, based on Phase 2a clinical results [2] Financial Results - Soligenix reported no revenues for the year ended December 31, 2025, compared to $0.1 million in the previous year, primarily due to the conclusion of a zero-margin grant for HyBryte™ [3] - The net loss for 2025 was $11.1 million, or ($2.14) per share, an increase from $8.3 million, or ($4.98) per share, in 2024, attributed to higher R&D costs and decreased other income [4] - Research and development expenses rose to $7.5 million in 2025 from $5.2 million in 2024, mainly due to costs associated with the Phase 2 study in Behçet's Disease and the ongoing Phase 3 CTCL study [5] - General and administrative expenses were $4.4 million in 2025, slightly up from $4.2 million in 2024, due to increased taxes and stock-related expenses [6] - As of December 31, 2025, the company's cash position was approximately $7.9 million [6]

Core Insights - The latest episode of The BioMedWire Podcast features Dr. Christopher Schaber, CEO of Soligenix Inc., discussing the company's Phase 3 FLASH2 study for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) [2][6]. Company Overview - Soligenix Inc. is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs [8]. - The company is advancing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy for CTCL, with plans for potential commercialization following successful Phase 3 study completion [9]. Study Insights - The upcoming interim analysis of the Phase 3 FLASH2 study will assess safety and efficacy, with a focus on whether to continue patient enrollment or stop early for overwhelming efficacy [3][4]. - Initial assumptions for the study included a 40% response rate for HyBryte™ and 10% for placebo, leading to a conservative aggregate blinded response rate of 25% [5]. - At the 50-patient mark, the blinded aggregate response rate was reported at 48%, significantly exceeding initial expectations [5]. Future Outlook - The interim analysis and top-line results are anticipated to be transformational for the company, potentially leading to commercialization and partnerships for HyBryte™ [6]. - The company has conducted multiple positive studies leading up to this Phase 3 trial, indicating a de-risked development program [6].

Core Viewpoint - Soligenix, Inc. announced the publication of a clinical summary for HyBryte™ in the journal "Expert Opinion on Investigational Drugs," highlighting its potential as a treatment for cutaneous T-cell lymphoma (CTCL) [1][2]. Clinical Trials and Efficacy - HyBryte™ (synthetic hypericin) has shown promising results in clinical trials, with a unique mechanism of action and an excellent safety profile, positioning it as a potential first-line treatment for early-stage CTCL [3][4]. - In the Phase 3 FLASH trial, 16% of patients treated with HyBryte™ achieved at least a 50% reduction in lesions compared to 4% in the placebo group, demonstrating statistical significance (p=0.04) [5]. - The second treatment cycle showed a 40% response rate in patients receiving 12 weeks of HyBryte™ treatment, significantly higher than the placebo group [6]. - In the optional third treatment cycle, 49% of patients who received HyBryte™ throughout all cycles demonstrated a positive treatment response [7]. Safety Profile - HyBryte™ is noted for its safety, with no evidence of systemic absorption or DNA damage, making it a safer alternative to current therapies that carry significant side effects [8]. - The treatment has been well tolerated across all three treatment cycles, with no serious safety issues reported [7][8]. Regulatory Status and Future Studies - HyBryte™ has received orphan drug and fast track designations from the FDA, and orphan designation from the EMA, facilitating its development for CTCL [4]. - A second confirmatory Phase 3 study, FLASH2, is underway, with an interim analysis expected in Q2 2026, aiming to replicate the successful design of the first FLASH study [9][10]. - The FDA has awarded a $2.6 million Orphan Products Development grant to support an investigator-initiated study for expanded treatment of HyBryte™ in early-stage CTCL [12]. Market Context - CTCL is a rare form of non-Hodgkin's lymphoma affecting approximately 31,000 individuals in the U.S. and 38,000 in Europe, with no current approved front-line therapies available [13][14]. - Soligenix is focused on addressing unmet medical needs in rare diseases, with HyBryte™ as a key product in its pipeline [14].

Core Viewpoint - Soligenix, Inc. announced that its product SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Behçet's Disease, marking a significant step towards potential early access for patients with severe conditions [1][2]. Group 1: Product Development and Designation - SGX945 has been granted PIM designation, which is a prerequisite for inclusion in the UK Early Access to Medicines Scheme (EAMS) [1]. - The PIM designation criteria include a favorable benefit-risk balance, major advantages over current treatments, and addressing a life-threatening condition with high unmet medical need [1]. - The company aims to leverage the EAMS scheme to expedite the availability of SGX945 to patients suffering from Behçet's Disease [1]. Group 2: Clinical Data and Efficacy - Dusquetide has shown positive efficacy results in Phase 2 and 3 clinical studies, including a 40% improvement in ulcer reduction compared to placebo in Behçet's Disease patients [1]. - The treatment demonstrated sustained improvement, with a 32% improvement at Week 8 after treatment cessation, compared to apremilast's 41% improvement at the same time point [1]. - SGX945 was well-tolerated with no treatment-related adverse events reported, contrasting with common side effects associated with apremilast [1]. Group 3: Market Context and Disease Overview - Behçet's Disease is an inflammatory disorder with significant symptoms affecting quality of life, including mouth sores, skin rashes, and genital ulcers, impacting approximately 18,000 known cases in the U.S. and over 50,000 in Europe [2]. - Current treatments for Behçet's Disease primarily manage symptoms and include corticosteroids and immunosuppressants, which have limited long-term efficacy and significant side effects [2]. - Apremilast is the only approved drug for Behçet's Disease, used as a maintenance therapy, but it requires continuous administration and is associated with high costs and side effects [2].

Core Viewpoint - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs, and it will present at the BIO Investment & Growth Summit on March 2, 2026 [1] Company Overview - Soligenix is developing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and is seeking regulatory approvals following the successful completion of its second Phase 3 study [1] - The company is also expanding its product pipeline, which includes SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [1] - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine, and vaccines targeting filoviruses and COVID-19, utilizing the ThermoVax® heat stabilization technology [1] Upcoming Events - Christopher J. Schaber, Ph.D., President & CEO of Soligenix, will deliver a corporate presentation at the BIO Investment & Growth Summit on March 2, 2026, in Miami Beach, Florida [1] Funding and Support - The development of Soligenix's vaccine programs has been supported by government grants and contracts from agencies such as NIAID, DTRA, and BARDA [1]

Core Insights - Soligenix, Inc. has completed the enrollment of 50 patients for the interim analysis in its Phase 3 study of HyBryte™ for treating cutaneous T-cell lymphoma (CTCL) [1][2] - The interim analysis is expected to occur in the second quarter of 2026, with a planned overall blinded study response rate of 25% [2][10] - The study builds on previous successful trials, demonstrating a response rate of 48% among patients who have completed the treatment phase to date [2][4] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs [16] - The company is advancing HyBryte™ (SGX301), a novel photodynamic therapy utilizing synthetic hypericin, for the treatment of CTCL [16][3] - The company also has other development programs targeting conditions such as psoriasis and inflammatory diseases [16] Study Details - The FLASH2 study is a randomized, double-blind, placebo-controlled trial enrolling approximately 80 subjects with early-stage CTCL [2][10] - The study design replicates the first successful Phase 3 FLASH study, extending the treatment to 18 weeks without breaks [10][11] - Previous studies indicated a treatment response of 49% in patients completing 18 weeks of therapy in the first Phase 3 study [11][6] Treatment Efficacy - HyBryte™ has shown a response rate of 75% in an ongoing investigator-initiated study, with a benign safety profile observed [2][5] - The treatment has demonstrated significant anti-proliferative effects on malignant T-cells and has received orphan drug and fast track designations from the FDA [5][10] - The first Phase 3 study showed a statistically significant improvement in lesion reduction compared to placebo [6][7] Market Context - CTCL is a rare form of non-Hodgkin's lymphoma affecting approximately 31,000 individuals in the U.S. and 38,000 in Europe [15][14] - There is currently no approved front-line therapy for CTCL, making HyBryte™ a potentially safer and effective treatment option [9][14] - The FDA and EMA require a second successful Phase 3 trial for marketing approval, which Soligenix is currently pursuing with the FLASH2 study [10][19]

Core Viewpoint - Soligenix, Inc. is focused on advancing its late-stage biopharmaceutical pipeline, particularly in the treatment of rare diseases, with significant upcoming milestones and a strategic approach to resource allocation and potential partnerships [2][8]. Recent Accomplishments - The company announced the conclusion of the first Data Monitoring Committee (DMC) meeting for its Phase 3 study of HyBryte™, confirming no safety concerns and an acceptable safety profile consistent with prior studies [2][5]. - Soligenix expanded its Medical Advisory Board in Europe to enhance strategic guidance for the Phase 3 study of HyBryte™ [5]. - The company appointed Tomas J. Philipson, PhD, as a Strategic Advisor to leverage his extensive government relationships [5]. - The FDA granted orphan drug designation to dusquetide for the treatment of Behçet's Disease based on positive Phase 2a results [5]. Financial Results - For the quarter ended September 30, 2025, Soligenix reported no revenue, with a net loss of $2.5 million, or ($0.58) per share, compared to a net loss of $1.7 million, or ($0.78) per share for the same period in 2024 [4][5]. - Research and development expenses increased to $1.6 million from $1.0 million year-over-year, primarily due to costs associated with the Phase 3 CTCL trial [6]. - General and administrative expenses were $1.0 million, slightly up from $0.9 million in the previous year [7]. - The company's cash position was approximately $10.5 million as of September 30, 2025, providing sufficient operating runway through 2026 [2][7].

Core Insights - Soligenix, Inc. is advancing the Phase 3 clinical development of HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma [1][20] - The company has updated its Medical Advisory Board (MAB) to include key opinion leaders in CTCL to provide strategic guidance as it progresses with clinical studies and regulatory interactions [2][3] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs, including HyBryte™ for CTCL [20] - The company is also developing other products, including SGX302 for psoriasis and dusquetide (SGX942) for inflammatory diseases [20][21] Clinical Development - The FLASH Phase 3 trial enrolled 169 patients with Stage IA, IB, or IIA CTCL, demonstrating a 16% response rate for HyBryte™ compared to 4% for placebo in the first treatment cycle [10] - In the second treatment cycle, a 40% response rate was observed among patients receiving 12 weeks of HyBryte™ treatment, significantly higher than the placebo group [11] - The third optional treatment cycle showed that 49% of patients who received HyBryte™ throughout all cycles demonstrated a positive treatment response [12] Safety and Efficacy - HyBryte™ is noted for its safety profile, as it is not associated with DNA damage, making it a safer alternative to current therapies that have significant side effects [13] - The treatment has received orphan drug and fast track designations from the FDA, indicating its potential for addressing unmet medical needs [9][16] Regulatory Pathway - Following the first Phase 3 study, both the FDA and EMA require a second successful Phase 3 trial for marketing approval, which is currently ongoing [14] - The FLASH2 study aims to replicate the successful design of the first trial while extending the treatment duration to 18 weeks [14] Market Potential - CTCL affects approximately 31,000 individuals in the U.S. and 38,000 in Europe, with around 3,200 and 3,800 new cases annually, respectively [19] - The company anticipates accelerated enrollment in the FLASH2 study due to its engagement with the CTCL community and previous trial experiences [14]

Core Insights - Soligenix, Inc. is progressing with its confirmatory Phase 3 FLASH2 study for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL), with no safety concerns reported by the Data Monitoring Committee [1][2] - The study aims to enroll approximately 80 patients and is on track for an enrollment update in Q4 2025, with an interim efficacy analysis expected in the first half of 2026 [1][2] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, particularly through its Specialized BioTherapeutics segment [15] - The company is also involved in developing other products, including treatments for psoriasis and inflammatory diseases [15][16] Product Details - HyBryte™ (SGX301) is a novel photodynamic therapy using synthetic hypericin, activated by visible light, which has shown promising efficacy and safety in previous studies [3][4] - The FLASH2 study builds on the previous successful Phase 3 FLASH study, which demonstrated a 49% treatment response rate in patients completing 18 weeks of therapy [5][9] Clinical Study Design - FLASH2 is a randomized, double-blind, placebo-controlled, multicenter study that extends the treatment duration to 18 weeks without breaks, aiming to provide a more realistic assessment of HyBryte™'s efficacy [2][10] - The primary endpoint assessment will occur at the end of the 18-week treatment period, with the study replicating key design components from the first FLASH study [9][10] Regulatory Status - HyBryte™ has received orphan drug and fast track designations from the FDA, indicating its potential for expedited review due to the rarity of CTCL [4][12] - The FDA and EMA have indicated that a second successful Phase 3 trial is necessary for marketing approval, which the FLASH2 study aims to fulfill [9][10] Market Context - CTCL is a rare form of non-Hodgkin's lymphoma, affecting approximately 31,000 individuals in the U.S. and 38,000 in Europe, with limited treatment options available [13][14] - The safety profile of HyBryte™ is a significant advantage, as it avoids the risks associated with traditional therapies that can lead to severe side effects, including secondary malignancies [8][12]

Core Viewpoint - Soligenix, Inc. is expanding its European Medical Advisory Board to enhance strategic guidance for the Phase 3 study of HyBryte™ in treating cutaneous T-cell lymphoma (CTCL), with top-line results expected in the second half of 2026 [1][2]. Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, particularly through its Specialized BioTherapeutics segment [20]. - The company is advancing HyBryte™ (SGX301), a novel photodynamic therapy utilizing synthetic hypericin, aimed at treating CTCL [20]. Clinical Study Details - The confirmatory Phase 3 study, named FLASH2, will enroll approximately 80 patients and is designed to replicate the successful elements of the previous Phase 3 FLASH trial, which showed a 49% treatment response rate [15]. - The FLASH2 study will extend the double-blind, placebo-controlled assessment to 18 weeks, with the primary endpoint assessed at the end of this period [15]. Advisory Board Expansion - The European Medical Advisory Board now includes five esteemed dermatologists, enhancing the company's expertise in clinical strategies and regulatory interactions [2][3][4][7][8]. - The board members are recognized leaders in the field of dermatology and CTCL, contributing valuable insights for the upcoming clinical study [2][3][4][7][8]. Treatment Mechanism and Efficacy - HyBryte™ employs synthetic hypericin activated by visible light, which penetrates deeper into the skin compared to ultraviolet light, potentially treating more severe skin conditions [9]. - In previous studies, HyBryte™ demonstrated a statistically significant improvement in lesion reduction compared to placebo, with a 16% response rate in the first treatment cycle [10]. Safety Profile - HyBryte™ is noted for its safety, with no systemic absorption and a mechanism of action that does not involve DNA damage, making it a safer alternative to existing therapies [14]. - The treatment has been well tolerated across multiple cycles, with a significant portion of patients opting to continue treatment in the optional safety cycle [13]. Market Context - CTCL is a rare form of non-Hodgkin's lymphoma affecting approximately 31,000 individuals in the U.S. and 38,000 in Europe, with no current cure available [19][18]. - The company aims to address the significant safety risks associated with existing treatments, positioning HyBryte™ as a potentially safer and effective option for patients [14].